<< Oral salmon calcitonin using absorption-enhancing Eligen Technology holds promise for osteoarthritis | Report on the Malaysian pharmaceuticals and healthcare industry >>

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Norsk | Русский | Svenska | Polski

Antisense Pharma's SAPPHIRE Phase III trial evaluating trabedersen approved by Health Canada

Published on October 19, 2009 at 7:58 AM · No Comments

Study to examine trabedersen vs. current standard chemotherapy in patients with recurrent or refractory anaplastic astrocytoma

The biopharmaceutical company Antisense Pharma GmbH has announced today that it has received the approval by Health Canada for its pivotal Phase III clinical trial SAPPHIRE in patients with recurrent or refractory anaplastic astrocytoma.

The SAPPHIRE study is a randomized, active-controlled, clinical trial designed to confirm the efficacy and safety of the investigational drug trabedersen (AP 12009), observed in previous clinical studies. Trabedersen is being investigated as monotherapy compared to current standard therapy with temozolomide (alternatively BCNU (carmustine)). The results of a previous randomized, active-controlled Phase IIb study show that the novel, targeted therapy holds significant promise. Currently recruiting study centers will be published on www.anticancer.de.

Source: ANTISENSE PHARMA GMBH

01a880a2-87a5-41db-978b-e94929238a29|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Angiogenesis, Antisense, Brain, Brain Tumor, Cancer, Catheter, Chemotherapy, Colorectal Cancer, Glioblastoma, Glioma, Hospital, Life Expectancy, Melanoma, Metastasis, Oligonucleotides, Oncology, Pancreatic Cancer, Radiotherapy, Temozolomide

Related posts

Increases in VEGF-family markers in metastatic colorectal cancer patients associated with Avastin resistanceCircadian Technologies Limited announced today the presentation of data at the American Society of C...
Survival rates of wealthier patients with glioblastoma are longer than poorer patientsSurvival rates of wealthier patients and those younger than 70 with glioblastoma, the most common an...
Trilink, TATAA sign deal to sell CleanAmp ProductsTriLink BioTechnologies, Inc. announced that it has entered into a distribution agreement with TATAA...
National monitoring essential for preventing emergence of malaria drug resistanceWHO is calling on countries to be increasingly vigilant in monitoring antimalarial drug efficacy in ...
Infinity announces Phase 1b/2 clinical trial of IPI-926 in patients with metastatic pancreatic cancerInfinity Pharmaceuticals, Inc. today announced that enrollment is ongoing locally for a Phase 1b/2 c...
UC San Diego proferssor awarded 2010 Harvey Prize in human health by TechnionMichael Karin, PhD, Distinguished Professor of Pharmacology and Pathology at the University of Calif...
New article published in Journal of Surgical Research highlights PACE technologySANUWAVE Health, Inc., an emerging medical technology company focused on the development and commerc...
Delcath Systems' trial meets primary endpoint of extended hPFS in patients with melanoma metastasesDelcath Systems, Inc., a development stage, oncology-focused, specialty pharmaceutical and medical d...
Saint Mary's and Sierra Neurosurgery Group partner to create Nevada's first Brain Tumor CenterSaint Mary's and Sierra Neurosurgery Group have partnered to create the region's first Brain Tumor C...
Dutasteride reduces risk of prostate cancerThere is good news for those at high risk for prostate cancer. The drug dutasteride which is manufac...
Clinical data of dendritic cell based vaccine to be presented at Cancer Stem Cells ConferenceImmunoCellular Therapeutics announced today that Manish Singh, Ph.D., President and CEO, will be pre...
Reversing protein deficiency through gene therapy can improve SMAReversing a protein deficiency through gene therapy can correct motor function, restore nerve signal...
Nanotechnology plays a key role in detection and treatment of cancerA world-renowned medical researcher discusses the key role that nanotechnology has begun to play in ...
Isis Pharmaceuticals adds ISIS-APOCIIIRx to its development pipeline to treat TGIsis Pharmaceuticals, Inc. announced today that it has added a new drug, ISIS-APOCIIIRx, to its deve...
New technique to cool the brains of cardiac arrest patientsThe first randomized intra-arrest cooling study performed using a novel intra-nasal cooling method s...
Medulloblastoma in children - two studies find clues to treatmentMedulloblastoma is one of the most common and most malignant brain tumours among children and teenag...
Researchers publish MRI images of genes in action in the living brainBiologists have just confirmed what poets have known for centuries: eyes really are windows of the s...
Novel catheter technique for patching holes in the heartA novel catheter technique for patching holes in the heart may make it possible for many patients to...
One-a-day tablet treats common infectionA bioadhesive tablet containing the antifungal drug miconazole is an effective and convenient means ...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.